Product
BIMERVAX
2 clinical trials
3 indications
Indication
COVID-19Indication
InfluenzaIndication
HumanClinical trial
A Phase I/IIa Study to Evaluate Safety and Immunogenicity of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy VolunteersStatus: Completed, Estimated PCD: 2021-09-30
Clinical trial
Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX as Heterologous Booster for the Prevention of Coronavirus Disease 2019 (COVID-19) in Adolescents From 12 Years to Less Than 18 Years of Age.Status: Recruiting, Estimated PCD: 2024-12-30